Total Payments
$31,375
2024 Payments
$4,591
Companies
84
Transactions
1,392
Medicare Patients
2,251
Medicare Billing
$286,831
Payment Breakdown by Category
Food & Beverage$25,638 (81.7%)
Other$3,200 (10.2%)
Education$1,737 (5.5%)
Travel$799.75 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $25,638 | 1,353 | 81.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,200 | 1 | 10.2% |
| Education | $1,737 | 36 | 5.5% |
| Travel and Lodging | $799.75 | 2 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | $6,051 | 87 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,254 | 138 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,073 | 120 | $0 (2024) |
| Amgen Inc. | $1,540 | 82 | $0 (2023) |
| PFIZER INC. | $1,383 | 106 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,382 | 74 | $0 (2024) |
| Genentech USA, Inc. | $1,132 | 63 | $0 (2024) |
| Incyte Corporation | $918.56 | 42 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $896.85 | 32 | $0 (2024) |
| GENZYME CORPORATION | $731.69 | 38 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,591 | 196 | Merck Sharp & Dohme LLC ($391.73) |
| 2023 | $4,049 | 187 | Rigel Pharmaceuticals, Inc. ($599.46) |
| 2022 | $4,221 | 198 | Rigel Pharmaceuticals, Inc. ($429.57) |
| 2021 | $3,105 | 165 | Rigel Pharmaceuticals, Inc. ($374.04) |
| 2020 | $1,726 | 96 | Novartis Pharmaceuticals Corporation ($214.73) |
| 2019 | $7,227 | 190 | Rigel Pharmaceuticals, Inc. ($4,447) |
| 2018 | $2,822 | 173 | E.R. Squibb & Sons, L.L.C. ($280.61) |
| 2017 | $3,634 | 187 | Millennium Pharmaceuticals, Inc. ($463.73) |
All Payment Transactions
1,392 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $29.59 | General |
| Category: Oncology | ||||||
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.70 | General |
| Category: Oncology | ||||||
| 12/17/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.17 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $22.51 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $42.82 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $11.72 | General |
| Category: HORMONE THERAPY | ||||||
| 12/05/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $11.40 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $22.70 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $29.82 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: BioOncology | ||||||
| 11/18/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.48 | General |
| Category: Hematology/Oncology | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.73 | General |
| Category: Oncology | ||||||
| 11/05/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $22.35 | General |
| Category: Hematology | ||||||
| 11/04/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Education | In-kind items and services | $74.99 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 445 | 1,441 | $101,081 | $58,101 |
| 2022 | 14 | 513 | 1,979 | $125,430 | $68,357 |
| 2021 | 15 | 618 | 2,079 | $134,739 | $78,145 |
| 2020 | 17 | 675 | 2,300 | $167,005 | $82,228 |
Total Patients
2,251
Total Services
7,799
Medicare Billing
$286,831
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 57 | 162 | $32,400 | $21,481 | 66.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 74 | 209 | $33,440 | $18,424 | 55.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 50 | $7,500 | $4,495 | 59.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 73 | $8,760 | $4,373 | 49.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 56 | $5,880 | $3,786 | 64.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 52 | 223 | $5,650 | $2,305 | 40.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 34 | $2,380 | $1,423 | 59.8% |
| J1750 | Injection, iron dextran, 50 mg | Office | 2023 | 13 | 47 | $1,210 | $634.12 | 52.4% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 20 | 36 | $1,440 | $544.94 | 37.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 22 | 29 | $435.00 | $220.69 | 50.7% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 26 | 67 | $670.00 | $215.07 | 32.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 14 | 16 | $96.00 | $94.08 | 98.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 24 | 45 | $450.00 | $54.95 | 12.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 32 | 351 | $609.00 | $33.45 | 5.5% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 23 | 43 | $161.00 | $15.66 | 9.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 326 | $52,120 | $29,632 | 56.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 53 | 91 | $18,200 | $11,642 | 64.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 108 | $16,200 | $8,390 | 51.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 53 | 80 | $8,400 | $5,088 | 60.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 79 | $9,480 | $4,189 | 44.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 65 | 346 | $8,650 | $3,745 | 43.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 26 | 74 | $5,180 | $2,711 | 52.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 18 | $3,600 | $1,733 | 48.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 16 | 29 | $1,160 | $515.18 | 44.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 23 | 37 | $555.00 | $284.45 | 51.3% |
About Dr. Ester Pollard, MD
Dr. Ester Pollard, MD is a Hematology & Oncology healthcare provider based in Corpus Christi, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225002843.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ester Pollard, MD has received a total of $31,375 in payments from pharmaceutical and medical device companies, with $4,591 received in 2024. These payments were reported across 1,392 transactions from 84 companies. The most common payment nature is "Food and Beverage" ($25,638).
As a Medicare-enrolled provider, Pollard has provided services to 2,251 Medicare beneficiaries, totaling 7,799 services with total Medicare billing of $286,831. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Corpus Christi, TX
- Active Since 02/13/2006
- Last Updated 02/28/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1225002843
Products in Payments
- Tavalisse (Drug) $5,297
- OPDIVO (Biological) $1,849
- KEYTRUDA (Biological) $1,284
- Rezlidhia (Drug) $738.41
- PROMACTA (Drug) $681.89
- JAKAFI (Drug) $655.90
- XTANDI (Drug) $487.62
- Lenvima (Drug) $472.64
- JEVTANA (Drug) $465.55
- FOTIVDA (Drug) $421.19
- BESREMI (Drug) $414.83
- TECENTRIQ (Biological) $383.14
- BENDEKA (Drug) $369.42
- Lonsurf (Drug) $365.57
- Kyprolis (Drug) $362.63
- SCEMBLIX (Drug) $358.62
- LYNPARZA (Drug) $357.48
- Kyprolis (Biological) $352.49
- DOPTELET (Drug) $345.28
- IBRANCE (Drug) $325.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.